Clinical Trials on Granuloma, Plasma Cell in China

Total 4883 results

First Affiliated Hospital of Zhejiang University

Unknown

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Multiple Myeloma

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Multiple Myeloma

China
Jinling Hospital, China

Unknown

Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma (CTd)

Multiple Myeloma

China
Yongping Zhai

Unknown

Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

Multiple Myeloma

China
Wuhan University
Tongji Hospital

Unknown

The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy (HLJDT-2016)

Multiple Myeloma

China
Peking University First Hospital

Recruiting

A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM

Multiple Myeloma | Renal Injury

China
Southwest Hospital, China

Unknown

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia | Multiple Myeloma

China
Shanghai Jiao Tong University School of Medicine

Suspended

Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma

Multiple Myeloma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Multiple Myeloma

China
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
Affiliated Hospital of Nantong University

Recruiting

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Multiple Myeloma

China
Second Affiliated Hospital, School of Medicine,...
Shaoxing People's Hospital; Shaoxing Second Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Multiple Myeloma

China
First Hospital of China Medical University

Recruiting

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Multiple Myeloma

China
LanZhou University
Beijing Health Alliance Charitable Foundation

Recruiting

Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma

Multiple Myeloma

China
Li Zheng

Not yet recruiting

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Multiple Myeloma

China
Sichuan University

Recruiting

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Multiple Myeloma

China
Zhejiang University
OriCell Therapeutics Co., Ltd.

Active, not recruiting

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Multiple Myeloma

China
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaborators

Unknown

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Multiple Myeloma

China
Beijing Chao Yang Hospital

Enrolling by invitation

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

Multiple Myeloma | Bortezomib

China
Shanghai Jiao Tong University School of Medicine

Terminated

Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Multiple Myeloma

China
Peking University First Hospital

Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Multiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes | Monoclonal Gammopathy of Undetermined... and other conditions

China
Yongyong MA

Recruiting

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Amyloid Light-chain Amyloidosis

China
The First Affiliated Hospital of Soochow University

Recruiting

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Multiple Myeloma

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Jiangsu Province... and other collaborators

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Active, not recruiting

Cohort Construction and Prognostic Model Construction for Multiple Myeloma

Multiple Myeloma

China
Zhongnan Hospital

Completed

Plasma-free Replacement in Patients With Multiple Myeloma

Multiple Myeloma

China
Second Military Medical University
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Unknown

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

China
Peking Union Medical College Hospital
Beijing Immunochina Medical Science & Technology Co., Ltd.

Unknown

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (BDH-WM01)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (BDH-WM02)

Waldenström Macroglobulinemia

China
Gracell Biotechnologies Ltd.

Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Sanofi

Completed

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

China
Peking Union Medical College Hospital

Unknown

Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma

China
Shanghai Children's Medical Center

Unknown

Chronic Granulomatous Disease Study in China

Granulomatous Disease, Chronic

China
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Liao Aijun

Recruiting

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Bendamustine

China
Peking University People's Hospital
Qingdao Municipal Hospital

Recruiting

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement (SPODUMENE)

Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China

Clinical Trials on Granuloma, Plasma Cell in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations